Centenial Surgical Suture Ltd posts ₹0.74 crore Q1 profit

Centenial Surgical Suture Ltd posted a standalone net profit of ₹0.74 crore in the June 2026 quarter, compared with a ₹0.04 crore loss a year earlier, while revenue increased 18.55% to ₹15.34 crore. The result marks a return to profitability for the medical-device manufacturer in the first quarter of FY27.

What did Centenial Surgical Suture Ltd report in Q1 FY27?

Centenial Surgical Suture reported revenue of ₹15.34 crore and net profit of ₹0.74 crore for the quarter ended June 30, 2026. The company had reported revenue of ₹12.94 crore and a net loss of ₹0.04 crore in the corresponding June 2025 quarter. Earnings per share improved to ₹2.01 from a loss per share of ₹0.11.

The quarterly figures show both sales growth and a move back into the black after the prior-year loss. The company manufactures and sells surgical sutures and other medical devices in India and international markets. Its June-quarter operating profit stood at ₹2.18 crore, compared with ₹1.23 crore in June 2025.

How did the June 2026 result compare with recent quarters?

Centenial Surgical Suture's June 2026 revenue of ₹15.34 crore was higher than ₹12.58 crore in the March 2026 quarter and ₹14.86 crore in the December 2025 quarter. It was also above the ₹13.46 crore reported for September 2025. The June 2026 quarter was the highest revenue figure in the quarterly data supplied from June 2023 onward.

Profitability also improved sequentially. The company reported a net loss of ₹2.31 crore in March 2026, after a profit of ₹0.15 crore in December 2025 and a marginal loss of ₹0.01 crore in September 2025. Profit before tax moved to ₹0.98 crore in June 2026 from a loss of ₹2.23 crore in March 2026. Expenses in June 2026 were ₹13.16 crore, compared with ₹11.71 crore a year earlier, while sales rose at a faster absolute pace.

What do the figures indicate about Centenial Surgical Suture's operations?

The June-quarter result indicates that Centenial Surgical Suture generated stronger operating profit alongside higher revenue. Operating profit rose to ₹2.18 crore in June 2026 from ₹1.23 crore in June 2025, and the operating profit margin based on the reported sales and operating-profit figures was about 14.2%, versus about 9.5% a year earlier.

The improvement follows a period of uneven quarterly performance. Revenue had declined 5.73% year-on-year to ₹13.46 crore in the September 2025 quarter, based on an earlier company result update. The March 2026 quarter then recorded revenue of ₹12.58 crore and a net loss of ₹2.31 crore. Against that sequence, the June 2026 result provides a clearer comparison point for investors assessing the sustainability of sales and profitability in subsequent disclosures.

How has the market context affected investors?

The supplied market data states that Raaj Medisafe India Ltd delivered a 31.0% return over the past year and outperformed Centenial Surgical Suture by 62.9 percentage points. This comparison indicates that the company's share performance lagged that peer measure over the stated period, despite the reported June-quarter earnings turnaround.

Trading data also recorded an abnormal price movement in Centenial Surgical Suture's scrip on October 19, 2026. The filing cited only one trade at ₹71.25 on that day. Limited trading activity can make individual transactions more prominent, so investors tracking the stock may consider liquidity alongside the company's reported quarterly financial performance.

What is the next disclosed event for Centenial Surgical Suture?

Centenial Surgical Suture has scheduled a board meeting for November 12, 2026, to consider and approve standalone unaudited financial results for the quarter and half-year ended September 30, 2026. The meeting intimation was issued under Regulations 29 and 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The September 2026 results will offer the next reported measure of whether the June-quarter improvement continued. The company had reported September 2025 net sales of ₹13.46 crore and a net loss of ₹0.01 crore. Investors will be able to compare the forthcoming disclosure with both that prior-year period and the June 2026 revenue of ₹15.34 crore.

Conclusion

Centenial Surgical Suture's June 2026 quarter showed a return to standalone profitability, with net profit of ₹0.74 crore against a ₹0.04 crore loss a year earlier. Revenue growth of 18.55%, higher operating profit and EPS of ₹2.01 were the central financial developments in the quarter.

The next item to watch is the board's consideration of September 2026 standalone results on November 12, 2026. That disclosure will show whether the higher June-quarter sales and operating profitability were maintained through the first half of FY27.